Merck reveals positive results from KEYTRUDA® Plus Phase 3 trial
Category: #health  By Pankaj Singh  Date: 2019-10-01
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck reveals positive results from KEYTRUDA® Plus Phase 3 trial

Breast cancer is initiated when genes regulating cell growth mutate. These mutations allows the cells to divide and multiply rampantly and are formed in the ducts or lobules of the breast. Several pharmaceutical firms are developing novel treatments to effectively treat this prevailing disease.

Merck & Co., Inc., is one such firm based in New Jersey that recently announced clinical results from its neoadjuvant/adjuvant KEYNOTE-522 Phase 3 trial assessing KEYTRUDA, the pharmaceutical’s anti-PD-1 therapy targeted towards patients with early-stage TNBC (triple-negative breast cancer).

According to reports, the trial investigated a regimen of neoadjuvant KEYTRUDA followed by adjuvant KEYTRUDA as monotherapy. Moreover, interim findings from the first randomized trial of an anti-PD-1 therapy for TNBC were been presented at the European Society for Medical Oncology (ESMO) 2019 Congress.

Speaking on the announcement, Dr. Roger M. Perlmutter, President, Merck Research Laboratories, said that this trial is first to deploy a combined adjuvant and neoadjuvant treatment with KEYTRUDA in patients with early-stage TNBC. He said that the results of the KEYNOTE-522 study are very encouraging and indicate the potential of the drug to change the treatment of patients diagnosed with TNBC.

As for Dr. Peter Schmid, lead at the Centre for Experimental Cancer Medicine, Barts Cancer Institute, there is a significant need for novel treatment regimens that could increase the pCR rates in this patient population and the KEYTRUDA plus chemotherapy in the neoadjuvant setting and the positive trend for event free-survival demonstrated in this trial could significantly help improve pCR rates.

Prior to this announcement, Merck had revealed that the European Commission has approved KEYTRUDA, as the first-line treatment for patients suffering from advanced RCC (renal cell carcinoma). Apparently, the approval was based on the findings from the Phase 3 KEYNOTE-426 trial, which revealed that KEYTRUDA, along with axitinib, reduced the risk of death by 47% compared with sunitinib in patients with advanced RCC.

Source Credit: https://www.mrknewsroom.com/news-release/oncology/mercks-keytruda-pembrolizumab-plus-chemotherapy-showed-statistically-significa



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Vertex announces reimbursement of ORKAMBI and SYMDEKO in Australia
Vertex announces reimbursement of ORKAMBI and SYMDEKO in Australia
By Pankaj Singh

Vertex Pharmaceuticals Inc. is a global biopharmaceutical company that is relentless in striving for medical excellence while developing transformative therapies for life-threatening and serious diseases, such as cysti...

Centene, RxAdvance and Walgreens unveil new pharmacy management model
Centene, RxAdvance and Walgreens unveil new pharmacy management model
By Pankaj Singh

The cloud adoption trend is increasingly picking up momentum across a plethora of industry disciplines. Among these, the healthcare and pharmaceutical sector is emerging as a prominent cloud subscriber globally. Numero...

Incyte unveils positive results from Phase 2 ruxolitinib cream study
Incyte unveils positive results from Phase 2 ruxolitinib cream study
By Pankaj Singh

Vitiligo is a prominent skin diseases prevalent across the world that causes skin color loss. The disease is increasingly being taken as a serious issue by various pharmaceutical firms across the globe, who are continu...